Profile data is unavailable for this security.
About the company
Celcuity Inc. is a clinical-stage biotechnology company, which develops targeted therapies for the treatment of multiple solid tumor indications. Its lead therapeutic candidate is gedatolisib, a potent, small molecule reversible inhibitor, that selectively targets all Class I isoforms of phosphatidylinositol-3-kinase (PI3K) and the two mechanistic target of rapamycin (mTOR) sub-complexes, mTORC1 and mTORC2. Its initial clinical development programs for gedatolisib are focusing on the treatment of patients with hormone receptor positive (HR+), human epidermal growth factor receptor 2 negative (HER2-), or HR+/HER2-, advanced or metastatic breast cancer and patients with metastatic castration resistant prostate cancer. Its VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant with or without palbociclib in patients with HR+/HER2- advanced breast. Its CELsignia companion diagnostic platform is able to analyze live patient tumor cells to identify new groups of cancer patients.
- Revenue in USD (TTM)0.00
- Net income in USD-73.45m
- Incorporated2017
- Employees55.00
- LocationCelcuity Inc16305 36th Ave N Ste 100MINNEAPOLIS 55446-4285United StatesUSA
- Phone+1 (763) 392-0767
- Fax+1 (302) 655-5049
- Websitehttps://www.celcuity.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lexeo Therapeutics Inc | 0.00 | -69.42m | 494.18m | 58.00 | -- | 2.70 | -- | -- | -2.71 | -2.71 | 0.00 | 5.56 | 0.00 | -- | -- | 0.00 | -47.71 | -- | -54.30 | -- | -- | -- | -- | -- | -- | -- | 0.0091 | -- | -100.00 | -- | -12.01 | -- | -- | -- |
IGM Biosciences Inc | 2.11m | -236.92m | 496.39m | 216.00 | -- | 3.07 | -- | 235.81 | -4.31 | -4.31 | 0.0375 | 2.74 | 0.005 | -- | -- | 9,397.32 | -56.49 | -44.66 | -62.57 | -48.20 | -- | -- | -11,255.25 | -23,668.96 | -- | -- | 0.00 | -- | 99.25 | -- | -11.45 | -- | 73.48 | -- |
Travere Therapeutics Inc | 155.72m | -415.73m | 503.21m | 380.00 | -- | 6.79 | -- | 3.23 | -5.32 | -2.00 | 2.04 | 0.9732 | 0.2116 | 1.57 | 7.04 | 409,800.00 | -56.49 | -36.95 | -71.19 | -44.77 | 94.34 | 95.92 | -266.96 | -165.79 | 2.75 | -- | 0.836 | -- | 32.69 | -2.43 | -13.54 | -- | 16.49 | -- |
Larimar Therapeutics Inc | 0.00 | -45.08m | 503.40m | 42.00 | -- | 2.18 | -- | -- | -0.9666 | -0.9666 | 0.00 | 3.62 | 0.00 | -- | -- | 0.00 | -24.56 | -42.22 | -26.04 | -47.14 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -4.51 | -- | 8.71 | -- |
Astria Therapeutics Inc | 0.00 | -81.63m | 505.20m | 59.00 | -- | 1.85 | -- | -- | -2.32 | -2.32 | 0.00 | 6.70 | 0.00 | -- | -- | 0.00 | -27.34 | -64.48 | -28.18 | -68.34 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -40.62 | -- | -- | -- |
OmniAB Inc | 21.05m | -63.48m | 508.10m | 106.00 | -- | 1.68 | -- | 24.14 | -0.634 | -0.634 | 0.2103 | 2.57 | 0.055 | -- | 7.18 | 198,547.20 | -16.58 | -- | -17.48 | -- | -- | -- | -301.63 | -- | -- | -- | 0.00 | -- | -42.17 | -- | -126.65 | -- | -- | -- |
Adaptive Biotechnologies Corp | 174.50m | -215.06m | 514.32m | 709.00 | -- | 1.87 | -- | 2.95 | -1.48 | -1.48 | 1.20 | 1.87 | 0.2472 | 4.52 | 4.78 | 246,124.10 | -30.48 | -19.69 | -34.73 | -22.06 | 57.06 | 67.18 | -123.29 | -122.27 | 4.35 | -- | 0.00 | -- | -8.11 | 25.06 | -12.52 | -- | 11.11 | -- |
Celcuity Inc | 0.00 | -73.45m | 515.61m | 55.00 | -- | 3.80 | -- | -- | -2.79 | -2.79 | 0.00 | 4.35 | 0.00 | -- | -- | 0.00 | -41.61 | -37.32 | -44.44 | -39.16 | -- | -- | -- | -- | -- | -- | 0.2193 | -- | -- | -- | -57.99 | -- | -31.12 | -- |
Heron Therapeutics Inc | 132.10m | -80.95m | 518.25m | 126.00 | -- | -- | -- | 3.92 | -0.6156 | -0.6156 | 0.9316 | -0.2245 | 0.6021 | 1.20 | 2.26 | 1,048,405.00 | -36.90 | -53.55 | -56.71 | -71.24 | 57.08 | 52.52 | -61.28 | -170.12 | 1.90 | -- | 1.29 | -- | 17.99 | 10.40 | 39.26 | -- | -29.97 | -- |
Alector Inc | 96.41m | -120.61m | 519.51m | 244.00 | -- | 2.90 | -- | 5.39 | -1.39 | -1.39 | 1.12 | 1.86 | 0.1393 | -- | -- | 395,106.60 | -17.43 | -20.00 | -21.55 | -23.81 | -- | -- | -125.11 | -124.07 | -- | -- | 0.00 | -- | -27.36 | 28.52 | 2.19 | -- | 4.79 | -- |
Olema Pharmaceuticals Inc | 0.00 | -99.34m | 523.54m | 75.00 | -- | 2.21 | -- | -- | -2.02 | -2.02 | 0.00 | 4.23 | 0.00 | -- | -- | 0.00 | -43.24 | -30.06 | -48.01 | -31.40 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 7.76 | -- | -- | -- |
Entrada Therapeutics Inc | 162.87m | 23.49m | 530.02m | 160.00 | 25.03 | 1.96 | 19.78 | 3.25 | 0.6273 | 0.6273 | 4.79 | 8.02 | 0.3302 | -- | 3.89 | 1,024,359.00 | 4.76 | -- | 7.06 | -- | -- | -- | 14.42 | -- | -- | -- | 0.00 | -- | -- | -- | 92.93 | -- | -- | -- |
SIGA Technologies Inc | 157.02m | 79.26m | 537.69m | 45.00 | 6.90 | 3.26 | 6.73 | 3.42 | 1.10 | 1.10 | 2.20 | 2.32 | 0.7354 | 0.3631 | 10.32 | 3,489,424.00 | 37.12 | 22.34 | 47.49 | 27.56 | 87.71 | 88.65 | 50.48 | 41.14 | 2.19 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
Compass Pathways PLC (ADR) | 0.00 | -129.44m | 538.16m | 186.00 | -- | 2.08 | -- | -- | -2.37 | -2.37 | 0.00 | 3.79 | 0.00 | -- | -- | 0.00 | -53.68 | -40.85 | -57.32 | -44.48 | -- | -- | -- | -- | -- | -43.34 | 0.1009 | -- | -- | -- | -29.46 | -- | -12.68 | -- |
Taysha Gene Therapies Inc | 14.16m | -118.01m | 540.48m | 52.00 | -- | 10.04 | -- | 38.18 | -1.19 | -1.19 | 0.0896 | 0.2879 | 0.1112 | -- | -- | 272,230.80 | -92.70 | -- | -146.13 | -- | -- | -- | -833.60 | -- | -- | -- | 0.4315 | -- | 517.55 | -- | 32.80 | -- | -- | -- |
Holder | Shares | % Held |
---|---|---|
Perceptive Advisors LLCas of 31 Mar 2024 | 2.36m | 7.76% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 2.29m | 7.51% |
Soleus Capital Management LP (Investment Management)as of 31 Mar 2024 | 1.73m | 5.69% |
Commodore Capital LPas of 31 Mar 2024 | 1.56m | 5.11% |
Baker Bros. Advisors LPas of 31 Mar 2024 | 1.55m | 5.10% |
Eventide Asset Management LLCas of 31 Mar 2024 | 1.39m | 4.56% |
BlackRock Fund Advisorsas of 31 Mar 2024 | 1.01m | 3.32% |
Balyasny Asset Management LPas of 31 Mar 2024 | 881.93k | 2.90% |
The Vanguard Group, Inc.as of 31 Mar 2024 | 816.82k | 2.68% |
Samlyn Capital LLCas of 31 Mar 2024 | 689.76k | 2.27% |